表紙
市場調查報告書

淋巴球活性化遺傳基因3蛋白:開發中產品分析

Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 367843
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
淋巴球活性化遺傳基因3蛋白:開發中產品分析 Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 107 Pages
簡介

本報告提供以淋巴球活性化遺傳基因3蛋白(LAG-3)為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

淋巴球活性化遺傳基因3蛋白(LAG-3) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Crescendo Biologics Ltd
  • Enumeral Biomedical Holdings Inc
  • GlaxoSmithKline Plc
  • Icell Kealex Therapeutics
  • Incyte Corp
  • MacroGenics Inc
  • Merck & Co Inc
  • Novartis AG
  • Prima BioMed Ltd
  • Regeneron Pharmaceuticals Inc
  • Sutro Biopharma Inc
  • Symphogen A/S
  • Tesaro Inc
  • Trellis Bioscience Inc
  • Xencor Inc

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2140TDB

Summary

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens.

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 34 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 7, 1, 13, 5 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Cardiovascular, Gastrointestinal and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Gastric Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Diffuse Large B-Cell Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Melanoma, Triple-Negative Breast Cancer (TNBC), Cervical Cancer, Hepatocellular Carcinoma, Lymphoma, Ovarian Cancer, Small-Cell Lung Cancer, Colon Carcinoma, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Mesothelioma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Renal Cell Carcinoma, Non-Hodgkin Lymphoma, Advanced Malignancy, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Blood Cancer, Breast Cancer, Cardiovascular Disease, Chronic Inflammation, Chronic Lymphocytic Leukemia (CLL), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammatory Bowel Disease, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Merkel Cell Carcinoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Nasopharyngeal Cancer, Neuroendocrine Tumors, Peritoneal Cancer, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rheumatoid Arthritis, Soft Tissue Sarcoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2019, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
  • The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development
  • Abeome Corp
  • Avacta Life Sciences Ltd
  • BJ Bioscience Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Crescendo Biologics Ltd
  • Eli Lilly and Co
  • F-star Biotechnology Ltd
  • F. Hoffmann-La Roche Ltd
  • Fountain Biopharma Inc
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • I-Mab Biopharma Co Ltd
  • ILGEN Inc
  • Immutep Ltd
  • Incyte Corp
  • Innovent Biologics Inc
  • Leads Biolabs Inc
  • Leidos Health
  • Lipid Genomics Inc
  • MacroGenics Inc
  • Merck & Co Inc
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • Shanghai Henlius Biotech Inc
  • Stcube Inc
  • Sutro Biopharma Inc
  • Symphogen A/S
  • Xencor Inc
  • Y-Biologics
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles
  • (nivolumab + relatlimab) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AM-0003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVA-021 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Abeome Corp, H2 2019
  • Pipeline by Avacta Life Sciences Ltd, H2 2019
  • Pipeline by BJ Bioscience Inc, H2 2019
  • Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Crescendo Biologics Ltd, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by F-star Biotechnology Ltd, H2 2019
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Pipeline by Fountain Biopharma Inc, H2 2019
  • Pipeline by GigaGen Inc, H2 2019
  • Pipeline by GlaxoSmithKline Plc, H2 2019
  • Pipeline by I-Mab Biopharma Co Ltd, H2 2019
  • Pipeline by ILGEN Inc, H2 2019
  • Pipeline by Immutep Ltd, H2 2019
  • Pipeline by Incyte Corp, H2 2019
  • Pipeline by Innovent Biologics Inc, H2 2019
  • Pipeline by Leads Biolabs Inc, H2 2019
  • Pipeline by Leidos Health, H2 2019
  • Pipeline by Lipid Genomics Inc, H2 2019
  • Pipeline by MacroGenics Inc, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Novartis AG, H2 2019
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
  • Pipeline by Shanghai Henlius Biotech Inc, H2 2019
  • Pipeline by Stcube Inc, H2 2019
  • Pipeline by Sutro Biopharma Inc, H2 2019
  • Pipeline by Symphogen A/S, H2 2019
  • Pipeline by Xencor Inc, H2 2019
  • Pipeline by Y-Biologics, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019